Compared with redo-transcatheter aortic valve replacement (TAVR) for transcatheter heart valve (THV) failure, surgical explantation of TAVR is riskier, with earlier reintervention and higher 30-day mortality, but similar mid-term prognosis after landmark analysis, according to a new international registry of patients.